OncoSec Medical (NASDAQ:ONCS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

OncoSec Medical Trading Down 7.4 %

ONCS opened at $2.26 on Thursday. OncoSec Medical has a 12-month low of $0.74 and a 12-month high of $31.90. The stock has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $6.00.

OncoSec Medical (NASDAQ:ONCS – Get Rating) last announced its quarterly earnings results on Thursday, December 15th. The biotechnology company reported ($4.50) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On OncoSec Medical

Several large investors have recently added to or reduced their stakes in ONCS. Two Sigma Investments LP bought a new stake in shares of OncoSec Medical in the fourth quarter worth about $35,000. Renaissance Technologies LLC grew its holdings in OncoSec Medical by 48.8% during the 2nd quarter. Renaissance Technologies LLC now owns 72,898 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 23,900 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of OncoSec Medical by 653.7% in the first quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock worth $444,000 after buying an additional 334,849 shares during the period.

About OncoSec Medical

(Get Rating)

OncoSec Medical, Inc is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.